Same-day CAR-T production is established and refined through the comparison of novel vector and gene-editing strategies with classical methods. Both processes are then standardized to ensure consistent, clinical-scale use. It develops cutting-edge analytical assays - leveraging CRISPR off-target profiling, 3D ex vivo efficacy screens, and cytokine-release monitoring - to qualify edited cells for safety and potency. Finally, it conducts paired comparisons of the new rapid workflow versus traditional ex vivo culture to demonstrate equivalence or superiority in product quality.
Stephanie Camacho, PhD, is Vice President of Marketing at Kytopen, where she oversees the marketing strategy and execution, as well as product management for its cutting-edge RUO and GMP Flowfect® cellular engineering technology.
A seasoned life sciences leader with over two decades of experience, Stephanie specializes in commercializing transformative biotechnologies, including capital equipment and GMP-ready platforms. She has a strong track record in driving growth through product strategy, building high-performing teams, and developing strategic partnerships across emerging and established organizations. Prior to joining Kytopen, Stephanie was Senior Director, Marketing at CellFE, a cellular engineering startup.
Stephanie holds a PhD in biochemistry and immunology from Freie Universität Berlin, Germany.
